teglicar   Click here for help

GtoPdb Ligand ID: 12976

Synonyms: compound 17 [Giannessi et al., 2003] | ST-1326 | ST1326
PDB Ligand
Compound class: Synthetic organic
Comment: Teglicar (ST1326) is a reversible carnitine palmitoyltransferase inhibitor [2]. It is a substrate analogue that mimics palmitoylcarnitine. Teglicar has been investigated for anti-cancer effects in solid [1] and liquid tumours [3-5].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 20
Topological polar surface area 81.26
Molecular weight 399.61
XLogP 5.15
No. Lipinski's rules broken 2
Click here for help
InChI InChI=1S/C22H45N3O3/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-23-22(28)24-20(18-21(26)27)19-25(2,3)4/h20H,5-19H2,1-4H3,(H2-,23,24,26,27,28)/t20-/m1/s1
1. Cacciola NA, Sepe F, Fioriniello S, Petillo O, Margarucci S, Scivicco M, Peluso G, Balestrieri A, Bifulco G, Restucci B et al.. (2023)
The Carnitine Palmitoyltransferase 1A Inhibitor Teglicar Shows Promising Antitumour Activity against Canine Mammary Cancer Cells by Inducing Apoptosis.
Pharmaceuticals (Basel), 16 (7). [PMID:37513899]
2. Giannessi F, Pessotto P, Tassoni E, Chiodi P, Conti R, De Angelis F, Dell'Uomo N, Catini R, Deias R, Tinti MO et al.. (2003)
Discovery of a Long-Chain Carbamoyl Aminocarnitine Derivative, a Reversible Carnitine Palmitoyltransferase Inhibitor with Antiketotic and Antidiabetic Activity.
Jourmal of Medicinal Chemistry, 46 (2): 303–309. DOI: 10.1021/jm020979u
3. Gugiatti E, Tenca C, Ravera S, Fabbi M, Ghiotto F, Mazzarello AN, Bagnara D, Reverberi D, Zarcone D, Cutrona G et al.. (2018)
A reversible carnitine palmitoyltransferase (CPT1) inhibitor offsets the proliferation of chronic lymphocytic leukemia cells.
Haematologica, 103 (11): e531-e536. [PMID:29930162]
4. Pacilli A, Calienni M, Margarucci S, D'Apolito M, Petillo O, Rocchi L, Pasquinelli G, Nicolai R, Koverech A, Calvani M et al.. (2013)
Carnitine-acyltransferase system inhibition, cancer cell death, and prevention of myc-induced lymphomagenesis.
J Natl Cancer Inst, 105 (7): 489-98. [PMID:23486551]
5. Ricciardi MR, Mirabilii S, Allegretti M, Licchetta R, Calarco A, Torrisi MR, Foà R, Nicolai R, Peluso G, Tafuri A. (2015)
Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias.
Blood, 126 (16): 1925-9. [PMID:26276667]
6. Rufer AC, Lomize A, Benz J, Chomienne O, Thoma R, Hennig M. (2007)
Carnitine palmitoyltransferase 2: analysis of membrane association and complex structure with a substrate analog.
FEBS Lett, 581 (17): 3247-52. [PMID:17585909]
7. Rufer AC, Thoma R, Benz J, Stihle M, Gsell B, De Roo E, Banner DW, Mueller F, Chomienne O, Hennig M. (2006)
The crystal structure of carnitine palmitoyltransferase 2 and implications for diabetes treatment.
Structure, 14 (4): 713-23. [PMID:16615913]